Aug. 6 at 1:26 PM
$ABCL
CFO A. Booth:
“AbCellera continues to be in a strong liquidity position with over
$565 million in cash and equivalents and with roughly
$110 million in available committed government funding”
CEO Hansen said re the business development:
2 new T cell engager partnerships “are adding over
$110 million in upfront cash to our balance sheet.
“Under the terms of the deal, AbCellera will receive
$28 million in upfront payments” from Vertex,
and the Jazz collaboration includes “3 confirmed discovery programs with
$84 million in total near-term upfront payments” and eligibility “to receive over
$2 billion in potential downstream payments…
The total potential deal value with all 5 programs included would be over
$4 billion.”
The board added 2 independent directors:
Dr. Victor Stander & Dr. Lynn Sealy as new Independent Directors on AbCellera’s Board.
